<DOC>
	<DOCNO>NCT02514694</DOCNO>
	<brief_summary>LEO 32731 ( `` Study Drug '' ) investigational drug develop LEO Pharma A/S ( `` Sponsor '' ) treatment psoriasis . The aim ( ) Study determine : - The safety tolerability Study Drug side effect might associate - The Study also measure much Study Drug get blood long time take body remove .</brief_summary>
	<brief_title>LEO 32731 - A Phase I Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subjects , prior study related activity , give write informed consent participate study abide study restriction . 2 . Subjects males female nonchildbearing potential 18 55 year age . 3 . Subjects body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive . 4 . For Group C , subject woman nonchildbearing potential . 5 . Subjects must good health . 1 . Male subject willing , whose partner willing , use appropriate contraception . 2 . Subjects receive prescribed systemic topical medication within 14 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . 3 . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . 4 . Subjects receive medication , include St John 's Wort ( dietary restriction , Section 6.2.3 ) , know chronically alter drug absorption elimination process within 30 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . 5 . Subjects significant history drug allergy determine Investigator . 6 . Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator . 7 . Subjects supine blood pressure supine pulse rate screen high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 50 bpm , respectively . 8 . Subjects positive urine drug screen alcohol breath test result screen first admission . 9 . Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological , dermatological major disorder determine Investigator . 10 . Subjects clinically significant illness within 4 week start dose administration determine Investigator . 11 . Subjects know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test HIV antibody . 12 . Active tuberculosis history incompletely treated tuberculosis , base medical history medical report . 13 . Subjects , opinion General Practitioner ( GP ) Investigator , participate study . 14 . Subjects one positive faecal occult blood test ( immunochemical method ) 2 assessment time screen Day1 checkin . 15 . Subjects â‰¥ 3 bowel movements/day . 16 . Subjects previously take part withdrawn study . 17 . Subjects , opinion Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>